The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Mitigating immune-related AEs in patients with autoimmune conditions
Yinghong Wang, MD, PhD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses strategies to reduce the occurrence of immune-related adverse events (AEs) in patients with autoimmune diseases. In general, early diagnosis and subsequent treatment is vital to minimize the severity of any side effects. For gastrointestinal AEs, endoscopy can assess the severity of the condition, and for patients with colitis, immunotherapy can be continued to be administered, even after diagnosis. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
